CutisPharma Unveils New Research and Development Center Massachusetts Senator Bruce Tarr Joins Commemoration of Company’s Acceleration of Pipeline Development for FDA Approvals
CutisPharma Announces Launch of Two New Compounding Kit Families Metronidazole and Baclofen Kits Enable Safe, Easy and Compliant Preparation by Pharmacists
CutisPharma Appoints Steven Dinh as Chief Scientific Officer Filling of Key Role Accelerates Company's Efforts to Develop Drug Portfolio Toward NDA Filings and FDA Approvals
Benefits of FIRST®-Vancomycin Presented at 13th Biennial ASA Congress. Stability of antimicrobial activity demonstrated in scientific abstract presentation.
Superior stability of FIRST®-Vancomycin highlighted in peer-reviewed study. Compared to extemporaneously compounded vancomycin in study published in IJPC.
|Upcoming Trade Shows|
Dec 4-7 Las Vegas, NV
Jan 8-11 Ponte Vedra Beach, FL